Related content

The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics

By Cresci Sharon  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. : 2577-2591

Informa Healthcare

Access to resources Recommend Favorite

PPAR-&ggr; Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-06 ,pp. : 292-300

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 10, 2012-05 ,pp. : 1206-1213

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist: Implications for Cardiovascular Disease in Patients with Diabetes Mellitus

By Cavender Matthew A.   Lincoff A. Michael  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 209-216

Adis International

Access to resources Recommend Favorite

Pharmacogenetics and Inflammatory Bowel Disease

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 6, Iss. 3, 2008-09 ,pp. : 201-224

Bentham Science Publishers

Access to resources Recommend Favorite